Great Lakes Advisors LLC Reduces Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Great Lakes Advisors LLC decreased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 44,245 shares of the medical equipment provider's stock after selling 5,714 shares during the quarter. Great Lakes Advisors LLC owned about 0.06% of Lantheus worth $3,958,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Prosperity Financial Group Inc. lifted its stake in shares of Lantheus by 13.9% during the 4th quarter. Prosperity Financial Group Inc. now owns 4,712 shares of the medical equipment provider's stock worth $422,000 after acquiring an additional 575 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Lantheus during the 4th quarter worth approximately $136,000. Amundi lifted its stake in shares of Lantheus by 529.5% during the 4th quarter. Amundi now owns 176,952 shares of the medical equipment provider's stock worth $16,633,000 after acquiring an additional 148,842 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Lantheus during the 4th quarter worth approximately $6,037,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Lantheus during the 4th quarter worth approximately $36,183,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,109 shares of company stock worth $5,105,606. 1.50% of the stock is currently owned by company insiders.

Remove Ads

Lantheus Stock Performance

NASDAQ LNTH traded up $1.06 on Wednesday, reaching $103.28. 505,580 shares of the stock traded hands, compared to its average volume of 937,124. The company has a fifty day moving average price of $92.35 and a 200-day moving average price of $96.64. The company has a market cap of $7.07 billion, a price-to-earnings ratio of 17.18 and a beta of 0.38. Lantheus Holdings, Inc. has a 12 month low of $56.52 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LNTH. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.